In the News

2020

June 29, 2020
Sekar Kathiresan showcases historic monkey data in hunt for a once-and-done gene editing approach to prevent heart attacks
Endpoints News
June 27, 2020
In its first tough test, CRISPR base editing slashes cholesterol levels in monkeys
STAT News
June 27, 2020
A ‘Cure for Heart Disease’? A Single Shot Succeeds in Monkeys
The New York Times
June 18, 2020
Big Tech Zeros In on the Virus-Testing Market
The New York Times
June 17, 2020
Biotech Startups Look to Test Employees for Covid-19 in Bid to Get Back to Normal
The Wall Street Journal
June 16, 2020
For some biotech employees in the age of COVID-19, the workday starts at the bathroom sink
The Boston Globe
June 11, 2020
Verve Therapeutics to Take On Heart Disease With $63 Million Funding Round
The Wall Street Journal
June 11, 2020
Verve banks $63M to move gene-editing heart attack treatment toward clinic
FierceBiotech
June 11, 2020
Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes
Xconomy
June 11, 2020
Verve raises another $63m to develop gene-editing treatment for heart disease
The Boston Globe

2019

June 11, 2019
10-year-old’s cholesterol was over 800. Can CRISPR fix the problem?
The Philadelphia Inquirer
May 10, 2019
One-off injection may drastically reduce heart attack risk
The Guardian
May 7, 2019
With a superstar cardiologist as its CEO, new CRISPR company targets heart disease
STAT
May 7, 2019
One of the world’s top experts in coronary heart disease is spearheading a new gene editing upstart out to transform the field
Endpoints News

Media Contact
Gina Nugent
Ten Bridge Communications
(617) 460-3579
gina@tenbridgecommunications.com